Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy.
Kim SJ, You D, Jeong IG, Song C, Hong B, Kim CS, Ahn H, Hong JH.
J Cancer Res Clin Oncol. 2019 Aug;145(8):2131-2140. doi: 10.1007/s00432-019-02956-6. Epub 2019 Jun 21.
PMID:31227894
Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
Wood DP.
J Urol. 2014 Feb;191(2):348-9. doi: 10.1016/j.juro.2013.10.133. Epub 2013 Oct 29.
PMID:24411846
Coexistence of Malakoplakia and Papillary Urothelial Carcinoma of the Urinary Bladder.
Prognostic significance of minor high grade component in non-invasive papillary urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a period of 3 years).
Syed M, Mushtaq S, Loya A, Hassan U, Mir K, Hussain M, Hameed M, Sheikh UN.
Ann Diagn Pathol. 2023 Apr;63:152079. doi: 10.1016/j.anndiagpath.2022.152079. Epub 2022 Dec 13.
PMID:36549142
Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
Abufaraj M, Foerster B, Schernhammer E, Moschini M, Kimura S, Hassler MR, Preston MA, Karakiewicz PI, Remzi M, Shariat SF.
Eur Urol. 2019 Apr;75(4):649-658. doi: 10.1016/j.eururo.2018.11.052. Epub 2018 Dec 13.
PMID:30553613
Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder.
Singh YP, Roy D, Jois B, Shetti M.
BMJ Case Rep. 2022 Apr 13;15(4):e249208. doi: 10.1136/bcr-2022-249208.